A Resources Roadmap to Recovery in the Greater Philadelphia Area
The Poison Control Center’s Opioid Assistance Resource (OAR) is organizing a 4-part virtual webinar series focusing on prescribing, family and pediatric approaches to opioid use disorder (OUD) care, and the landscape of substance and opioid treatment in Philadelphia.
This series is part of the OAR collection with support from the Health Federation of Philadelphia's Substance Use Response Guidance and Education (SURGE) program
About this event: Session #4 - November 16, 2022 @ 12:00-1:00 pm
This session will review trends in substance use and overdose in Philadelphia, PA, and the United States. Treatment recommendations including harm reduction resources and benefits will be discussed and resources available for patients in Philadelphia and throughout PA will be presented.
The Poison Control Center at CHOP’s Opioid Assistance Resource: The Poison Control Center at CHOP provides Philadelphia’s medical community with Opioid Assistance Resource support via our 24/7 phone line: 800-222-1222. OAR is here to help you with managing opioid toxicity and initiating buprenorphine for Opioid Use Disorder.
Presenter: Dr. Michael J. Lynch, MD
Dr. Lynch is the Medical Director of the Pennsylvania Department of Drug and Alcohol Programs (DDAP). In this position, Dr. Lynch advises and assists DDAP in the development of policy and procedures related to medical best practice as well as advances related to substance use disorder (SUD) treatment. Dr. Lynch graduated from the University of Notre Dame and University of Pittsburgh School of Medicine before completing his residency in emergency medicine and fellowship in medical toxicology at the University of Pittsburgh. He is an associate professor of Emergency Medicine, Medical Toxicology and Pediatrics at the University of Pittsburgh and works in the emergency department at UPMC Mercy Hospital. The toxicology service at UPMC is one of the busiest in the country, seeing patients at five Pittsburgh hospitals as well as providing inpatient addiction and telemedicine treatment. Dr. Lynch is an associate Medical Director at the Pittsburgh Poison Center and is Medical Director for Quality and SUD Services at UPMC Health Plan. He serves on the Board of Directors for the PA College of Emergency Physicians.
Moderator: Robert Bassett, DO – Associate Medical Director, Poison Control Center
Introduction: Rachel Linstead Goldsmith, MPA – Comprehensive Opioid Response &Education (CORE) Program Coordinator
Target Audience: This program is designed for Physicians, Nurse Practitioners (NPs), Physician Assistants (PAs), Clinical Nurse Specialists (CNSs), Certified Registered Nurse Anesthetist (CRNAs), and Certified Nurse-Midwifes (CNMs) able to obtain an X waiver from SAMHSA to prescribe buprenorphine and their care team colleagues.
Learning Objectives: Upon completion of this live activity, participants will be able to:
- Describe trends in substance use and overdose.
- Review best practices for treatment of opioid withdrawal and opioid use disorder.
- Identify strategies for clinicians in assuring patients have access to harm reduction resources.
- Specify resources available to patients with Opioid Use Disorder (OUD) in the Philadelphia region.
Accreditation Statement: The Children's Hospital of Philadelphia is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement: The Children's Hospital of Philadelphia designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation in this learning activity meets requirements for 1 hr Opioid-related CME for PA medical Licensure.
Disclosure Statement: Michael J. Lynch, MD and Robert Bassett, DO (Speakers), Jeanette Trella, PharmD and Lauren Longo, MPH (Course Directors), and Joan Nolan, RN, Rachel Linstead Goldsmith, MPA and Tina Mannices (CME Planners) have no relevant financial relationship with an ineligible company to disclose.
Supported in part by the Philadelphia Department of Public Health